CDC25C Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-CDC25C antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CDC25C |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | human |
| Isotype | n/a |
| Format | epitope affinity purified |
| Size | 0.1 mg |
| Concentration | 1ug/ul |
| Applications | Immunohistochemistry (IHC) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: cdc25C (phospho-Ser216) antibody detects endogenous levels of cdc25C only when phosphorylated at serine 216. This gene is highly conserved during evolution and it plays a key role in the regulation of cell division. The encoded protein is a tyrosine phosphatase and belongs to the Cdc25 phosphatase family. It directs dephosphorylation of cyclin B-bound CDC2 and triggers entry into mitosis. It is also thought to suppress p53-induced growth arrest. Multiple alternatively spliced transcript variants of this gene have been described, however, the full-length nature of many of them is not known. [provided by RefSeq, Jul 2008] |
| Immunogen | Immunogen: The antiserum was produced against synthesized phosphopeptide derived from human cdc25C around the phosphorylation site of serine 216 (S-P-SP-M-P). |
| Other Names | n/a |
| Gene, Accession # | [CDC25C], NCBI: AAL05410.1 |
| Catalog # | MBS417529 |
| Price | $325 |
| Order / More Info | CDC25C Antibody from MYBIOSOURCE INC. |
| Product Specific References | Toyoshima-Morimoto F. et al. (2002) EMBO Rep. 3(4): 341-348.Ferguson AM. et al. (2005) Mol Cell Biol. 25(7): 2853-2860.Donzelli M. et al. (2003) EMBO Rep. 4(7): 671-677.Chen F. et al. (2002) Proc Natl Acad Sci U S A. 99(4): 1990-1995. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies